IRF3 and cancer: However, a pan-cancer analysis has demonstrated that elevated activation of the cGAS-STING pathway, particularly of IRF3, is associated with poor prognosis in patients diagnosed with specific types of cancer, including colorectal, prostate and lung adenocarcinomas [71].